Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lisata, GATC Use AI to Derisk and Accelerate Drug Development
Details : GATC’s MAT AI platform will analyze Lisata’s investigational drug, LSTA1 (certepetide), to identify optimized and derisked development opportunities across various indications.
Product Name : LSTA1
Product Type : Peptide
Upfront Cash : Undisclosed
March 05, 2025
Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration